DD298412A5 - Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele - Google Patents

Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele Download PDF

Info

Publication number: DD298412A5
Authority: DD; German Democratic Republic
Prior art keywords: minutes; cys; acetonitrile; lys; gly
Prior art date: 1989-04-27

Application number

DD89343270A

Other languages

German (de)

English (en)

Inventor

Nicholas A Saccomano

Robert A Volkmann

Original Assignee

��@��Kk��

��@��@��k��Kk��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-04-28

Filing date

1989-04-27

Publication date

1992-02-20

1989-04-27 Application filed by ��@��Kk��, ��@��@��k��Kk�� filed Critical ��@��Kk��

1992-02-20 Publication of DD298412A5 publication Critical patent/DD298412A5/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 116
229920001184 polypeptide Polymers 0.000 title claims abstract description 114
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 114
238000000034 method Methods 0.000 title claims abstract description 37
108090000312 Calcium Channels Proteins 0.000 title claims abstract description 16
102000003922 Calcium Channels Human genes 0.000 title claims abstract description 16
239000002858 neurotransmitter agent Substances 0.000 title claims abstract description 6
230000002461 excitatory amino acid Effects 0.000 title claims description 7
239000003257 excitatory amino acid Substances 0.000 title claims description 7
238000002360 preparation method Methods 0.000 title claims description 3
230000008569 process Effects 0.000 title claims description 3
239000005557 antagonist Substances 0.000 title 1
229920000768 polyamine Polymers 0.000 claims abstract description 22
239000002435 venom Substances 0.000 claims abstract description 21
231100000611 venom Toxicity 0.000 claims abstract description 21
210000001048 venom Anatomy 0.000 claims abstract description 21
241000238898 Agelenopsis aperta Species 0.000 claims abstract description 17
150000003839 salts Chemical class 0.000 claims abstract description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
241000607479 Yersinia pestis Species 0.000 claims abstract description 9
201000010099 disease Diseases 0.000 claims abstract description 8
239000000203 mixture Substances 0.000 claims abstract description 6
230000000903 blocking effect Effects 0.000 claims abstract description 4
241000239290 Araneae Species 0.000 claims abstract 4
241000238899 Agelenopsis Species 0.000 claims abstract 2
230000002964 excitative effect Effects 0.000 claims abstract 2
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 120
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 71
150000001875 compounds Chemical class 0.000 claims description 33
239000002245 particle Substances 0.000 claims description 32
239000002904 solvent Substances 0.000 claims description 31
239000011148 porous material Substances 0.000 claims description 30
239000003643 water by type Substances 0.000 claims description 26
238000001514 detection method Methods 0.000 claims description 23
210000004027 cell Anatomy 0.000 claims description 21
150000001413 amino acids Chemical group 0.000 claims description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
230000008061 calcium-channel-blocking effect Effects 0.000 claims description 9
231100000614 poison Toxicity 0.000 claims description 8
239000002574 poison Substances 0.000 claims description 8
241000124008 Mammalia Species 0.000 claims description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
239000011575 calcium Substances 0.000 claims description 5
229910052791 calcium Inorganic materials 0.000 claims description 5
230000001404 mediated effect Effects 0.000 claims description 5
ODDOYXKAHLKKQY-MMWGEVLESA-N Cys-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N ODDOYXKAHLKKQY-MMWGEVLESA-N 0.000 claims description 4
210000002569 neuron Anatomy 0.000 claims description 4
230000003387 muscular Effects 0.000 claims description 3
238000004544 sputter deposition Methods 0.000 claims description 3
208000024827 Alzheimer disease Diseases 0.000 claims description 2
201000006474 Brain Ischemia Diseases 0.000 claims description 2
206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
206010010904 Convulsion Diseases 0.000 claims description 2
208000006011 Stroke Diseases 0.000 claims description 2
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 2
206010008118 cerebral infarction Diseases 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
208000035475 disorder Diseases 0.000 claims description 2
206010015037 epilepsy Diseases 0.000 claims description 2
210000000663 muscle cell Anatomy 0.000 claims description 2
239000003053 toxin Substances 0.000 claims 5
231100000765 toxin Toxicity 0.000 claims 5
108700012359 toxins Proteins 0.000 claims 5
229940123247 Neurotransmitter antagonist Drugs 0.000 claims 3
GAFKBWKVXNERFA-QWRGUYRKSA-N Gly-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 GAFKBWKVXNERFA-QWRGUYRKSA-N 0.000 claims 1
HABYQJRYDKEVOI-IHPCNDPISA-N Trp-His-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CCCCN)C(=O)O)N HABYQJRYDKEVOI-IHPCNDPISA-N 0.000 claims 1
ILDJYIDXESUBOE-HSCHXYMDSA-N Trp-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N ILDJYIDXESUBOE-HSCHXYMDSA-N 0.000 claims 1
CGDZGRLRXPNCOC-SRVKXCTJSA-N Tyr-Cys-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CGDZGRLRXPNCOC-SRVKXCTJSA-N 0.000 claims 1
WURLIFOWSMBUAR-SLFFLAALSA-N Tyr-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O WURLIFOWSMBUAR-SLFFLAALSA-N 0.000 claims 1
230000005540 biological transmission Effects 0.000 claims 1
230000001419 dependent effect Effects 0.000 claims 1
230000004770 neurodegeneration Effects 0.000 claims 1
230000003518 presynaptic effect Effects 0.000 claims 1
210000001519 tissue Anatomy 0.000 claims 1
125000003275 alpha amino acid group Chemical group 0.000 description 22
238000004108 freeze drying Methods 0.000 description 12
210000003918 fraction a Anatomy 0.000 description 9
210000002196 fr. b Anatomy 0.000 description 7
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000003480 eluent Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
238000010561 standard procedure Methods 0.000 description 6
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
229940127291 Calcium channel antagonist Drugs 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000010828 elution Methods 0.000 description 4
238000005194 fractionation Methods 0.000 description 4
230000035479 physiological effects, processes and functions Effects 0.000 description 4
238000010183 spectrum analysis Methods 0.000 description 4
229910052786 argon Inorganic materials 0.000 description 3
YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
206010002383 Angina Pectoris Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
208000031229 Cardiomyopathies Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
208000000289 Esophageal Achalasia Diseases 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010030136 Oesophageal achalasia Diseases 0.000 description 2
208000006399 Premature Obstetric Labor Diseases 0.000 description 2
206010036600 Premature labour Diseases 0.000 description 2
208000003782 Raynaud disease Diseases 0.000 description 2
208000012322 Raynaud phenomenon Diseases 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
FKNHDDTXBWMZIR-GEMLJDPKSA-N acetic acid;(2s)-1-[(2r)-2-amino-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(O)=O.SC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O FKNHDDTXBWMZIR-GEMLJDPKSA-N 0.000 description 2
201000000621 achalasia Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
LIURIBSBVUMOJS-UHFFFAOYSA-N agatoxin 489 Natural products C1=CC=C2C(CC(=O)NCCCN(O)CCCNCCCNCCCCNCCCN)=CNC2=C1 LIURIBSBVUMOJS-UHFFFAOYSA-N 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
239000000470 constituent Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
108010060199 cysteinylproline Proteins 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
QBHKCXPTYJQDLE-UHFFFAOYSA-N n-[3-[3-[3-[4-(3-aminopropylamino)butylamino]propylamino]propyl-hydroxyamino]propyl]-2,5-dihydroxybenzamide Chemical compound NCCCNCCCCNCCCNCCCN(O)CCCNC(=O)C1=CC(O)=CC=C1O QBHKCXPTYJQDLE-UHFFFAOYSA-N 0.000 description 2
ICSMWVXZVJFMRP-UHFFFAOYSA-N n-[3-[3-[3-[4-(3-aminopropylamino)butylamino]propylamino]propyl-hydroxyamino]propyl]-4-hydroxybenzamide Chemical compound NCCCNCCCCNCCCNCCCN(O)CCCNC(=O)C1=CC=C(O)C=C1 ICSMWVXZVJFMRP-UHFFFAOYSA-N 0.000 description 2
FSGGDDPNTYEPDY-UHFFFAOYSA-N n-[3-[3-[4-(3-aminopropylamino)butylamino]propyl-hydroxyamino]propyl]-2-(4-hydroxy-1h-indol-3-yl)acetamide Chemical compound C1=CC(O)=C2C(CC(=O)NCCCN(O)CCCNCCCCNCCCN)=CNC2=C1 FSGGDDPNTYEPDY-UHFFFAOYSA-N 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
-1 polyethylene Polymers 0.000 description 2
208000026440 premature labor Diseases 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
QEJSRHCBTUVTTE-UHFFFAOYSA-N 2-(4-hydroxy-1h-indol-3-yl)acetamide Chemical compound C1=CC(O)=C2C(CC(=O)N)=CNC2=C1 QEJSRHCBTUVTTE-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 1
241000208140 Acer Species 0.000 description 1
ADYKROCSIOKCGW-UHFFFAOYSA-N Agel 489 Natural products NCCCNCCCCNCCCCNCCCN(O)CCCNC(=O)Cc1c[nH]c2ccccc12 ADYKROCSIOKCGW-UHFFFAOYSA-N 0.000 description 1
ZEDBMCPXPIYJLW-XHNCKOQMSA-N Asp-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O ZEDBMCPXPIYJLW-XHNCKOQMSA-N 0.000 description 1
QLCPDGRAEJSYQM-LPEHRKFASA-N Cys-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N)C(=O)O QLCPDGRAEJSYQM-LPEHRKFASA-N 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000533867 Fordia Species 0.000 description 1
102100028953 Gelsolin Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101001059150 Homo sapiens Gelsolin Proteins 0.000 description 1
SVJRVFPSHPGWFF-DCAQKATOSA-N Lys-Cys-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SVJRVFPSHPGWFF-DCAQKATOSA-N 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
206010042600 Supraventricular arrhythmias Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
210000000087 hemolymph Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
108010085325 histidylproline Proteins 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000001423 neocortical effect Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000010453 quartz Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/16—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Diabetes (AREA)
Insects & Arthropods (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Reproductive Health (AREA)

DD89343270A 1989-04-28 1989-04-27 Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele DD298412A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US34618189A	1989-04-28	1989-04-28

Publications (1)

Publication Number	Publication Date
DD298412A5 true DD298412A5 (de)	1992-02-20

Family

ID=23358305

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DD89343270A DD298412A5 (de)	1989-04-28	1989-04-27	Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
DD90340246A DD293959A5 (de)	1989-04-28	1990-04-27	Verfahren zur herstellung von polyaminen und polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DD90340246A DD293959A5 (de)	1989-04-28	1990-04-27	Verfahren zur herstellung von polyaminen und polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele

Country Status (25)

Country	Link
EP (2)	EP0696578A3 (fr)
JP (8)	JPH0774187B2 (fr)
KR (2)	KR920007554B1 (fr)
CN (2)	CN1038931C (fr)
AT (1)	ATE131813T1 (fr)
AU (1)	AU615144B2 (fr)
CA (2)	CA2015505C (fr)
CZ (1)	CZ283830B6 (fr)
DD (2)	DD298412A5 (fr)
DE (1)	DE69024253T2 (fr)
DK (1)	DK0395357T3 (fr)
EG (1)	EG19311A (fr)
ES (1)	ES2081929T3 (fr)
FI (1)	FI902139A7 (fr)
GR (1)	GR3018976T3 (fr)
HU (1)	HU223593B1 (fr)
IE (2)	IE69848B1 (fr)
IL (3)	IL112522A (fr)
NO (1)	NO300128B1 (fr)
NZ (2)	NZ233469A (fr)
PL (1)	PL165148B1 (fr)
PT (1)	PT93876B (fr)
RU (1)	RU2037498C1 (fr)
YU (1)	YU84590A (fr)
ZA (1)	ZA903229B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5122596A (en) *	1989-09-29	1992-06-16	Pfizer Inc.	Polypeptides useful as blockers of calcium channels
US5037846A (en) *	1990-01-02	1991-08-06	Pfizer Inc.	Indolyl-3 polyamines and their use as antagonists of excitatory amino acid neurotransmitters
US5312928A (en) *	1991-02-11	1994-05-17	Cambridge Neuroscience	Calcium channel antagonists and methodology for their identification
US5461032A (en) *	1991-03-01	1995-10-24	Fmc Corporation	Insecticidally effective peptides
US6011068A (en) *	1991-08-23	2000-01-04	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
ES2256370T3 (es) *	1991-08-23	2006-07-16	Nps Pharmaceuticals, Inc.	Moleculas activas para el receptor de calcio.
US5185369A (en) *	1991-08-23	1993-02-09	Pfizer Inc.	Synthetic heteroaryl polyamines as excitatory amino acid neurotransmitter antagonists
US6031003A (en) *	1991-08-23	2000-02-29	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
US5763569A (en) *	1991-08-23	1998-06-09	The Brigham And Women's Hospital, Inc	Calcium receptor-active molecules
US6313146B1 (en)	1991-08-23	2001-11-06	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
US5858684A (en) *	1991-08-23	1999-01-12	The Brigham And Women's Hospital, Inc.	Method of screening calcium receptor-active molecules
US5688938A (en) *	1991-08-23	1997-11-18	The Brigham & Women's Hospital, Inc.	Calcium receptor-active molecules
US6001884A (en) *	1991-08-23	1999-12-14	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
IL104419A0 (en) *	1992-01-24	1993-05-13	Fmc Corp	Insecticidally effective peptides
US5763568A (en) *	1992-01-31	1998-06-09	Zeneca Limited	Insecticidal toxins derived from funnel web (atrax or hadronyche) spiders
US5962314A (en) *	1993-02-23	1999-10-05	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
EP0637237B1 (fr) *	1993-02-23	2004-05-19	Brigham And Women's Hospital, Inc.	Molecules actives sur les recepteurs du calcium
US5457178A (en) *	1993-07-07	1995-10-10	Fmc Corporation	Insecticidally effective spider toxin
EP0729359A4 (fr) *	1993-11-15	1999-06-02	Baker Med Res Inst	Procede de traitement du dysfonctionnement cardiaque et compositions pharmaceutiques utilisables a cet effet
EP1203761B1 (fr)	1994-10-21	2005-01-19	Nps Pharmaceuticals, Inc.	Composés capables de moduler l'activité du récepteur de calcium
US5869602A (en) *	1995-03-17	1999-02-09	Novo Nordisk A/S	Peptide derivatives
US5756459A (en) *	1995-06-07	1998-05-26	Fmc Corporation	Insecticidally effective peptides isolatable from phidippus spider venom
US6271196B1 (en) *	1996-03-05	2001-08-07	Regents Of The University Of Ca	Methods of alleviating neuropathic pain using prosaposin-derived peptides
DK0907631T3 (da)	1996-05-01	2003-09-22	Nps Pharma Inc	Uorganiske ionreceptoraktive forbindelser
AUPO733397A0 (en) *	1997-06-13	1997-07-10	University Of Sydney, The	Pesticidal compounds
CN1071115C (zh) *	1998-08-07	2001-09-19	彭小平	一种治疗胃肠炎及溃疡的复方药
FR2802817B1 (fr) *	1999-12-23	2002-10-11	Centre Nat Rech Scient	Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
US20020197689A1 (en) *	2000-03-22	2002-12-26	Gerardo Corzo	Insecticidal peptides and methods for use of same
FR2820136A1 (fr) *	2001-01-26	2002-08-02	Aventis Pharma Sa	Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
FR2885129B1 (fr)	2005-04-29	2007-06-15	Proskelia Sas	Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
CN108949771B (zh) *	2018-08-02	2021-10-19	南京农业大学	拟环纹豹蛛c家族杀虫基因及其编码的成熟肽与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4950739A (en) *	1988-02-10	1990-08-21	New York University	Membrane calcium channels and factors and methods for blocking, isolating and purifying calcium channels
GB8820442D0 (en) *	1988-08-30	1988-09-28	Usherwood P N R	Therapeutic polyamine amides

1989
- 1989-04-27 DD DD89343270A patent/DD298412A5/de not_active IP Right Cessation
1990
- 1990-04-20 IL IL11252290A patent/IL112522A/xx active IP Right Grant
- 1990-04-20 IL IL9414790A patent/IL94147A/en not_active IP Right Cessation
- 1990-04-24 ES ES90304397T patent/ES2081929T3/es not_active Expired - Lifetime
- 1990-04-24 EP EP95105540A patent/EP0696578A3/fr not_active Withdrawn
- 1990-04-24 DE DE69024253T patent/DE69024253T2/de not_active Expired - Fee Related
- 1990-04-24 AT AT90304397T patent/ATE131813T1/de not_active IP Right Cessation
- 1990-04-24 EP EP90304397A patent/EP0395357B1/fr not_active Expired - Lifetime
- 1990-04-24 DK DK90304397.4T patent/DK0395357T3/da active
- 1990-04-26 PT PT93876A patent/PT93876B/pt not_active IP Right Cessation
- 1990-04-26 CA CA002015505A patent/CA2015505C/fr not_active Expired - Lifetime
- 1990-04-26 CA CA002194103A patent/CA2194103C/fr not_active Expired - Lifetime
- 1990-04-27 AU AU54535/90A patent/AU615144B2/en not_active Ceased
- 1990-04-27 ZA ZA903229A patent/ZA903229B/xx unknown
- 1990-04-27 RU SU904743764A patent/RU2037498C1/ru not_active IP Right Cessation
- 1990-04-27 KR KR1019900005987A patent/KR920007554B1/ko not_active Expired
- 1990-04-27 YU YU84590A patent/YU84590A/sh unknown
- 1990-04-27 PL PL90284973A patent/PL165148B1/pl unknown
- 1990-04-27 NZ NZ233469A patent/NZ233469A/en unknown
- 1990-04-27 IE IE149690A patent/IE69848B1/en not_active IP Right Cessation
- 1990-04-27 NO NO901881A patent/NO300128B1/no not_active IP Right Cessation
- 1990-04-27 CN CN90103929A patent/CN1038931C/zh not_active Expired - Lifetime
- 1990-04-27 HU HU9002610A patent/HU223593B1/hu not_active IP Right Cessation
- 1990-04-27 DD DD90340246A patent/DD293959A5/de not_active IP Right Cessation
- 1990-04-27 NZ NZ244480A patent/NZ244480A/en unknown
- 1990-04-27 IE IE950345A patent/IE950345L/xx unknown
- 1990-04-27 FI FI902139A patent/FI902139A7/fi not_active Application Discontinuation
- 1990-04-28 CZ CS902157A patent/CZ283830B6/cs not_active IP Right Cessation
- 1990-04-29 EG EG25490A patent/EG19311A/xx active
- 1990-05-01 JP JP2115704A patent/JPH0774187B2/ja not_active Expired - Fee Related
1992
- 1992-07-22 KR KR1019920013070A patent/KR930000163B1/ko not_active Expired - Fee Related
1994
- 1994-10-19 JP JP6253966A patent/JP2691141B2/ja not_active Expired - Fee Related
1995
- 1995-02-02 IL IL11252295A patent/IL112522A0/xx unknown
1996
- 1996-02-14 GR GR960400377T patent/GR3018976T3/el unknown
- 1996-03-11 CN CN96101787A patent/CN1136960A/zh active Pending
- 1996-06-24 JP JP8163247A patent/JP2746360B2/ja not_active Expired - Fee Related
- 1996-06-24 JP JP8163231A patent/JP2744904B2/ja not_active Expired - Fee Related
- 1996-06-24 JP JP8163255A patent/JP2746361B2/ja not_active Expired - Fee Related
- 1996-06-24 JP JP8163236A patent/JP2747279B2/ja not_active Expired - Fee Related
- 1996-06-24 JP JP8163234A patent/JP2746359B2/ja not_active Expired - Fee Related
- 1996-06-24 JP JP8163250A patent/JPH09118691A/ja active Pending

Also Published As

Publication number	Publication date
IL112522A0 (en)	1995-05-26
ATE131813T1 (de)	1996-01-15
JP2746361B2 (ja)	1998-05-06
NO901881L (no)	1990-10-29
RU2037498C1 (ru)	1995-06-19
JPH0774187B2 (ja)	1995-08-09
ES2081929T3 (es)	1996-03-16
EP0696578A3 (fr)	1998-04-29
PT93876B (pt)	1996-09-30
IE901496L (en)	1990-10-28
EP0696578A2 (fr)	1996-02-14
NZ233469A (fr)	1994-12-22
NZ244480A (fr)	1994-12-22
CA2194103A1 (fr)	1990-10-29
GR3018976T3 (en)	1996-05-31
KR920007554B1 (ko)	1992-09-07
KR900015745A (ko)	1990-11-10
HUT55415A (en)	1991-05-28
EP0395357B1 (fr)	1995-12-20
CN1136960A (zh)	1996-12-04
AU615144B2 (en)	1991-09-19
JPH0314551A (ja)	1991-01-23
IE69848B1 (en)	1996-10-02
JP2746359B2 (ja)	1998-05-06
YU84590A (sh)	1992-09-07
HU902610D0 (en)	1990-09-28
JPH07165793A (ja)	1995-06-27
JPH09118692A (ja)	1997-05-06
JPH09118694A (ja)	1997-05-06
IL112522A (en)	2005-12-18
NO300128B1 (no)	1997-04-14
KR930000163B1 (ko)	1993-01-11
PT93876A (pt)	1990-11-20
DE69024253T2 (de)	1996-05-15
CA2015505A1 (fr)	1990-10-28
JPH09118693A (ja)	1997-05-06
CN1047078A (zh)	1990-11-21
HU223593B1 (hu)	2004-09-28
IL94147A (en)	1998-10-30
JP2691141B2 (ja)	1997-12-17
JP2746360B2 (ja)	1998-05-06
DE69024253D1 (de)	1996-02-01
EP0395357A2 (fr)	1990-10-31
FI902139A7 (fi)	1990-10-29
CA2015505C (fr)	1997-03-11
NO901881D0 (no)	1990-04-27
JP2747279B2 (ja)	1998-05-06
CS215790A3 (en)	1992-02-19
IE950345L (en)	1990-10-28
IL94147A0 (en)	1991-01-31
ZA903229B (en)	1991-12-24
JP2744904B2 (ja)	1998-04-28
DD293959A5 (de)	1991-09-19
FI902139A0 (fi)	1990-04-27
CA2194103C (fr)	2000-01-04
AU5453590A (en)	1990-11-08
JPH09132596A (ja)	1997-05-20
EP0395357A3 (fr)	1992-04-01
JPH09118691A (ja)	1997-05-06
EG19311A (en)	1995-02-28
JPH09118690A (ja)	1997-05-06
CN1038931C (zh)	1998-07-01
CZ283830B6 (cs)	1998-06-17
PL165148B1 (en)	1994-11-30
DK0395357T3 (da)	1996-01-29

Legal Events

Date	Code	Title	Description
1996-06-20	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
JP2744904B2 (ja)	1998-04-28	興奮性アミノ酸神経伝達物質の拮抗物質として、および／またはカルシウムチャンネルの遮断剤として有用なポリペプチド
DE60102899T2 (de)	2005-03-31	Verfahren zur lösung von glucagon-ähnlichen peptid-1 (glp-1) verbindungen
EP0167575B1 (fr)	1993-05-26	Cardiodilatine, une nouvelle hormone peptidique et son procede de fabrication
DE69108830T2 (de)	1995-09-14	Neue im schwein vorkommende physiologisch aktive peptide.
DE69731097T2 (de)	2005-02-17	Conotoxin Peptide PVIIA
DE69313650T2 (de)	1998-01-08	Calcium-kanal blockierende polypeptide aus agelenopsis aperta
DE69007739T2 (de)	1994-07-07	Polypeptide verwertbar als Kalziumkanälen-Blocker.
DE69734885T2 (de)	2006-08-24	Klasse e-spannungsabhängiger calciumkanal-antagonist und verfahren
DE102004051014A1 (de)	2006-04-27	Chemisch modifizierte Peptidanaloga
DE60112424T2 (de)	2006-05-24	Protonen-abhängiges na+-kanal hemmendes polypeptid
DE69312320T2 (de)	1997-10-30	Den kalzium kanal blokierende polypeptide aus filistata hibernalis.
DE69318567T2 (de)	1998-09-10	Kalzium-kanal-blockierende polypeptide aus theraphosidae aphonopelma
DE69813232T2 (de)	2003-11-13	Wespe pompilid neuropeptide
DE69727155T2 (de)	2004-07-08	Dimesylatsalze von neuropeptiden und liganden
EP1023445B1 (fr)	2005-08-17	Facteur de croissance derive de la cadherine et son utilisation
DE69202136T2 (de)	1995-11-30	Neuartiges calcitonin, und seine herstellung und verwendung.
DE69907239T2 (de)	2004-04-01	Rho-conotoxin Peptide mit selektiver antagonistischer Aktivität auf den alpha-1-adrenozeptor
DE3704868C2 (de)	1995-09-21	Reinigung von rekombinantem Human-Interleukin-1
WO2001060844A2 (fr)	2001-08-23	Peptide et acide nucleique codant pour ce peptide pour la determination, le diagnostic et la therapie de maladies du systeme nerveux